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Abstract
Background: Airway instrumentation can evoke upper airway reflexes including bronchoconstriction and cough which can
cause serious complications including airway trauma, laryngospasm or bronchospasm which may in turn lead to difficulty
with ventilation and hypoxemia. These airway events are mediated in part by irritant-induced neuronal modulation of airway
tone and cough responses. We investigated whether the commonly used anesthetic agents dexmedetomidine, lidocaine or
remifentanil attenuated neuronal and airway smooth muscle responses in the upper airways of guinea pigs.
Methods: The ability of dexmedetomidine, lidocaine or remifentanil to attenuate direct cholinergic nerve stimulation,
C-fiber stimulation or direct smooth muscle contraction were studied using isolated tracheal rings from male guinea
pigs under four paradigms; (1) the magnitude of contractile force elicited by cholinergic electrical field stimulation
(EFS); (2) the amount of acetylcholine released during cholinergic EFS; (3) the direct airway smooth muscle relaxation of
a sustained acetylcholine-induced contraction and (4) the magnitude of C-fiber mediated contraction.
Results: Dexmedetomidine (1–100 μM) and lidocaine (1 mM) attenuated cholinergic 30Hz EFS-induced tracheal ring
contraction while remifentanil (10 μM) had no effect. Dexmedetomidine at 10 μM (p= 0.0047) and 100 μM (p= 0.01)
reduced cholinergic EFS-induced acetylcholine release while lidocaine (10 μM-1 mM) and remifentanil (0.1–10 μM) did not.
Tracheal ring muscle force induced by the exogenous addition of the contractile agonist acetylcholine or by a prototypical
C-fiber analogue of capsaicin were also attenuated by 100 μM dexmedetomidine (p= 0.0061 and p= 0.01, respectively).
The actual tracheal tissue concentrations of dexmedetomidine achieved (0.54–26 nM) following buffer application of
1–100 μM of dexmedetomidine were within the range of clinically achieved plasma concentrations (12 nM).
Conclusions: The α2 adrenoceptor agonist dexmedetomidine reduced cholinergic EFS-induced contractions and
acetylcholine release consistent with the presence of inhibitory α2 adrenoceptors on the prejunctional side of the
postganglionic cholinergic nerve-smooth muscle junction. Dexmedetomidine also attenuated both exogenous
acetylcholine-induced contraction and C-fiber mediated contraction, suggesting a direct airway smooth muscle effect and
an underlying mechanism for cough suppression, respectively.
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Background
Cough and bronchoconstriction are airway reflexes that
provide defense and protection for the respiratory tract
from inspired noxious agents and are thus a common
response to an airway foreign body such as an endo-
tracheal tube or suction catheter. However, during in-
duction and emergence from general anesthesia and
extubation in the intensive care unit, these protective
airway reflexes can cause serious complications, includ-
ing airway trauma, increased intracranial, intra-
abdominal or intraocular pressures, surgical bleeding,
wound dehiscence, cardiovascular instability, laryngos-
pasm and/or bronchospasm [1]. Moreover, in the inten-
sive care setting, obstructive airway diseases like asthma
and chronic obstructive pulmonary disease (COPD) can
complicate weaning from mechanical ventilation and
lead to weaning failures and multiple weaning attempts
[2]. These airway events occur in part by irritant-
induced neuronal modulation of airway reflexes and air-
way tone [3]. Activated afferent sensory fibers originat-
ing in the upper airway synapse in the nucleus of the
solitary tract which projects excitatory glutamatergic and
inhibitory γ-aminobutyric acid-A (GABAA)-ergic neu-
rons to the airway-related vagal preganglionic neurons
(AVPN). Parasympathetic nerves originate from the
AVPN, and after synapsing at parasympathetic ganglia
release acetylcholine from post-ganglionic cholinergic
nerves. The release of acetylcholine is dysregulated in
some animal models of asthma [4] and possibly in hu-
man asthmatics [5], suggesting a mechanistic basis for
clinically observed reflex-induced bronchoconstriction
following airway manipulation. By modulating receptors
on the pre-junctional side of postganglionic parasympa-
thetic nerves, acetylcholine release can be attenuated.
These receptors include M2 muscarinic, mu opioid [6],
GABAB [7], β2 adrenoceptor and α2 adrenoceptors [8].
Dexmedetomidine is a highly selective and potent α2
adrenoceptor agonist [9], and is known to produce both
hypnotic-anesthetic effects and analgesia in animal
models [10, 11] and humans [12, 13]. The drug causes
cooperative conscious sedation by stimulating the locus
coeruleus in the brain stem resulting in inhibition of the
sympathetic vasomotor center of the brain as opposed
to other sedatives (e.g. propofol, benzodiazepines) which
act upon GABAergic pathways causing unconsciousness.
Unlike other sedatives, dexmedetomidine does not cause
significant respiratory depression in clinically relevant
doses in either healthy volunteers [14] or surgical pa-
tients who require intensive care [15]. Intraoperative in-
fusions of dexmedetomidine reduce the requirement for
perioperative opioids [16], and reduce the hemodynamic
response to intubation and extubation [17]. These ad-
vantages of dexmedetomidine, along with a decrease in
saliva production, make dexmedetomidine an attractive
choice for sedation during awake fiberoptic intubation
[18] or for smooth extubation in both the operating
room and intensive care unit.
Many other medications have been utilized to optimize
the conditions for awake fiberoptic intubation including
topical and/or intravenous local anesthetics, opioids and
benzodiazepines. The clinical utility of these medications in
reducing airway responses during awake intubation or
emergence from anesthesia may also be mechanistically
explained by activation of pre-junctional receptors on post-
ganglionic parasympathetic nerves leading to decreased
acetylcholine release. We questioned whether dexmedeto-
midine, lidocaine or remifentanil attenuated acetylcholine
release from electrically field stimulated nerves in guinea
pig trachea and whether they attenuated airway smooth
muscle contraction induced by electrical field stimulation
(EFS), C fiber activation or exogenous acetylcholine.
Methods
Guinea pig tracheal rings in organ baths
Studies were approved by the Columbia University Ani-
mal Care and Use Committee (protocol number AC-
AAAH4701). Tracheal rings were isolated from male
Hartley guinea pigs under pentobarbital anesthesia. Con-
nective tissue and epithelium were removed and tracheal
rings were suspended in 4 ml water-jacketed organ baths
as previously described [19]. Organ baths contained
Krebs-Henseleit (KH) buffer of the following compos-
ition: (in mM): NaCl 118, KCl 5.6, CaCl2 0.5, MgSO4
0.2, NaHCO3 25, NaH2PO4 1.3, D-glucose 5.6, (pH 7.4)
with 10 μM indomethacin. The buffer was maintained at
37 °C and continuously bubbled with 95% O2/5% CO2.
The effects of the anesthetic agents dexmedetomidine,
lidocaine and remifentanil were then studied under four
paradigms in the absence or presence of these anesthetics;
(1) the magnitude of the contractile force induced by
cholinergic EFS; (2) the amount of acetylcholine released
into the buffer during cholinergic EFS stimulation; (3) the
relaxation of a sustained exogenous acetylcholine-induced
contraction; and (4) the magnitude of the contractile force
induced by exogenous capsaicin which activates transient
receptor potential cation channel subfamily V member 1
(TRPV1) receptors on C fibers which releases substance P
to cause airway smooth muscle contraction.
In those experiments in which acetylcholine released
into the buffer was measured during cholinergic EFS, the
buffer was further supplemented with 0.1 μM atropine,
10 μM guanethidine and 0.1 μM neostigmine. Atropine
was added to block presynaptic inhibitory muscarinic re-
ceptors on peripheral cholinergic nerves to maintain
stimulus-evoked release of acetylcholine [20]. Neostigmine
was used to prevent the degradation of released acetylcho-
line. Preliminary studies were performed to determine the
optimal concentration of neostigmine in the organ bath
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buffer that protected released acetylcholine from degrad-
ation without inhibiting the subsequent acetylcholine
detection assay. Guanethidine was included in the buffer
to prevent the release of norepinephrine from the sympa-
thetic nerves within the tracheal rings in response to EFS,
since catecholamines can modify airway cholinergic activ-
ity [21, 22].
Airway smooth muscle contractile response induced by
cholinergic electrical field stimulation
After equilibration of the guinea pig tracheal rings for 100
mins at a resting tension of 1 g with a change in the buffer
solution every 15 min, cholinergic EFS was delivered as
previously described [19]. In brief, a Grass S48 stimulator
(Grass Instrument/Natus Neurology, Warwick, RI) was
used with Med-Lab Stimu-Splitter II (Natus Neurology) to
deliver DC current (30 Hz, 24 V, 0.5 ms pulse width in
single 5 s trains, 0.013 trains/s) to tracheal rings. Following
stable EFS-induced contractions, 10 μM remifentanil,
100 μM dexmedetomidine, or 1 mM lidocaine were added
to the buffer with the continuous measurement of the
contractile force elicited by EFS. In a separate set of exper-
iments, cumulative concentrations of dexmedetomidine
(0.1–100 μM) were added to the buffer during cholinergic
EFS-induced contractions.
Acetylcholine release induced by EFS
In separate experiments, after equilibration of the tracheal
rings under 1 g resting tension for 100 mins, 0.1 μM atro-
pine, 10 μM guanethidine and 0.1 μM neostigmine were
added to the buffer for 30 min, followed by the application
of cholinergic EFS (2 Hz) for 15 min at which time the
organ bath buffer was collected. The organ bath was again
filled with new buffer with or without cumulatively increas-
ing concentrations of remifentanil (0.1–10 μM), lidocaine
(10 μM-1 mM), dexmedetomidine (1–100 μM) or tetrodo-
toxin (1 μM). Tracheal rings were incubated with each
concentration of the above test drugs for 30 min before
each 15 min EFS followed by collection of the organ bath
buffer for measurements of released acetylcholine. EFS was
applied to all the tracheal rings for four 15 min periods,
and one tracheal ring received only the drug vehicle and
served as a time control in each experiment. Each of the
collected aliquots of organ bath buffer (4 ml) were immedi-
ately frozen at -80C. Frozen buffer samples were lyophilized
(FreeZone 2.5 Plus, Labconco, Kansas City, MO) and
reconstituted with 500 μl water. Acetylcholine was
measured using a choline/acetylcholine quantitation kit
(Sigma-Aldrich, St. Louis, MO). Measured acetylcholine
were expressed as a percentage of that measured in the first
sample (first EFS) of each bath. EFS frequency was chosen
based on our previous experience [19] and published litera-
ture [23] to optimize acetylcholine release.
Airway smooth muscle contractile response induced by
exogenous acetylcholine and capsaicin
Tracheal rings were contracted with cumulatively increas-
ing concentrations of acetylcholine (0.1–100 μM) twice,
washed six times until resting tension was re-established
at 1 g, then contracted again with an approximate EC50
concentration of acetylcholine determined for each tra-
cheal ring (1–1.5 μM). After the achievement of a plateau
in the induced contractile force, dexmedetomidine (0.1–
100 μM) was added to the baths to measure the relaxation
of acetylcholine pre-contracted tracheal rings.
In separate experiments, tracheal rings were contracted
with cumulatively increasing concentrations of acetylcho-
line (0.1–100 μM) twice, washed six times until resting
tension was re-established at 1 g, then pretreated with
nothing, remifentanil (0.1–10 μM), lidocaine (10 μM–
1 mM), dexmedetomidine (1–100 μM) or 1 μM tetrodo-
toxin for 20 min before the addition of 10 μM N-vanillyl-
nonanamide (synthetic analogue of capsaicin) which
activates TRPV1 receptors on C fibers in this preparation
to release substance P resulting in smooth muscle con-
traction. The magnitude of the capsaicin-induced contrac-
tion was normalized to the initial maximal acetylcholine
contractile force for each individual tracheal ring.
Tracheal ring tissue dexmedetomidine concentration
measurement by mass spectrometry
After equilibration of the tracheal rings under 1 g resting
tension for 100 mins, dexmedetomidine (1–100 μM) was
added to the buffer for 30 mins, then the rings were briefly
rinsed in phosphate buffered saline (PBS) and blotted dry to
measure tissue weight. The tissues were homogenized in
PBS, centrifuged at 13,000 × g for 10 mins, and the super-
natant was collected and protein concentration was mea-
sured using the BCA Protein Assay Kit (Pierce, Thermo
Fisher Scientific, Waltham, MA). Dexmedetomidine (m/z
201.1.95.1) was quantified by HPLC – MS/MS after extrac-
tion with a 1:15 v/v solution of dichloromethane: methanol
(1:1) containing sphingomyelin C12 (d18:1/12:0, Avanti Polar
lipids) as an internal standard. Sixty μl of sample with known
protein concentrations and an external standard of dexme-
detomidine (range 0.78–100 μM) were extracted by vortex-
ing at room temperature overnight. After centrifugation to
precipitate resulting residues, 4 μl were injected into an Agi-
lent 1200 HPLC (Agilent Poroshell 120) linked to an Agilent
6430 triple quadrupole-tandem mass spectrometry (MS/
MS). Mobile phase A was methanol/water/chloroform/for-
mic acid (55:40:5:0.1 v/v); Mobile phase B was methanol/
acetonitrile/chloroform/formic acid (48:48:4:0.1 v/v). After
equilibration for 0.8 min at 95% mobile phase A, the gradient
was gradually increased to 95% mobile phase B that was held
for 5 min, and then was finally returned to 95% mobile phase
A to re-equilibrate for 2.35 min before the next injection.
The flow rate was 0.6 ml/min. The total run duration was
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9.25 min. All measurements were performed in triplicate
and were averaged. Agilent Mass Hunter Software (QQQ)
was used for quantitative analysis. Results were expressed
as pmol/mg protein, then converted to pmol/mg tissue
and finally to molar units since 1 g of tracheal ring tissue
was approximately 1 ml in volume.
Statistical analysis
Statistical analysis were performed using GraphPad Prism
4.03 software (GraphPad Software, Inc., La Jolla, CA). With
the small sample size, non-parametric Mann–Whitney ana-
lysis was performed to compare control and each drug
tested and p < 0.05 was considered statistically significant.
For comparisons with the same control group (the released
acetylcholine measurements and acetylcholine-induced
contractions with remifentanil and lidocaine), adjustments
on the significance level was done for the multiple concen-
tration points and p < 0.01 was considered statistically sig-
nificant. We presented results as means and standard error
of the mean. Sample sizes were determined using two-sided
5% type I error and a power of 80%. Based on our extensive
experience with the guinea pig wire myograph model, a
50% reduction of muscle contractile force was considered
significant with a 30% standard deviation. Therefore, n = 6
guinea pigs were needed for each wire myograph study. In
the study where released acetylcholine was measured, a
reduction of the release to 60% was considered biologically
significant, and an average of n = 7 guinea pigs were needed
with a 25% standard deviation.
Results
Dexmedetomidine (1–100 μM) and lidocaine (1 mM)
inhibited 30Hz EFS-induced cholinergic contractions in
guinea pig airway smooth muscle while remifentanil
(10 μM) had no effect (Fig. 1). Mean differences between
control and dexmedetomidine treatment were 51.4% at
1 μM (95.0 ± 4.72 vs 43.6 ± 5.44%) (p = 0.04), 50.9% at
10 μM (92.7 ± 8.54 vs 41.8 ± 6.57%) (p = 0.04), 53.0% at
25 μM (88.0 ± 7.98 vs 35.0 ± 5.57%) (p = 0.04), 53.4% at
50 μM (88.0 ± 9.62 vs 34.6 ± 6.96%) (p = 0.04) and 70.0%
at 100 μM (91.7 ± 9.59 vs 21.7 ± 7.06%) (p = 0.04). Remi-
fentanil attenuated EFS-induced cholinergic contractions
when the EFS frequency was lowered to 2Hz, and this
inhibition was reversed by adding 500 nM naloxone to
the organ bath buffer (data not shown). In an effort to
distinguish between neural release of acetylcholine ver-
sus direct inhibition of airway smooth muscle contrac-
tion, we measured acetylcholine liberated from the
tracheal rings into the organ bath buffer. Dexmedetomi-
dine (10–100 μM) attenuated EFS-induced acetylcholine
release while remifentanil (0.1–10 μM) and lidocaine
(10 μM–1 mM) did not (Fig. 2). The differences between
control and dexmedetomidine at 10 μM were 25.4%
(102 ± 4.47 vs 76.6 ± 8.29%; p = 0.0047) and 32.5% at
100 μM (97.5 ± 6.76 vs 65.0 ± 9.15%; p = 0.01). Tetrodo-
toxin, which is a sodium channel inhibitor known to
abolish neural release of acetylcholine [24], decreased
acetylcholine release and served as a positive control.
Tetrodotoxin (1 μM) showed a mean difference of 43.1%
(97.5 ± 6.76 vs 54.4 ± 15.1%; p = 0.04).
Fig. 1 Guinea pig tracheal ring muscle force generated in response to cholinergic electrical field stimulation (EFS). a Following stable EFS-induced contractions,
100 μM of dexmedetomidine, 10 μM remifentanil or 1 mM lidocaine or vehicle (0.1% DMSO) were added to buffer solution. Dexmedetomidine and lidocaine
inhibited EFS-induced contractions. b, c Dexmedetomidine attenuates guinea pig tracheal ring muscle force generated in response to cholinergic EFS
contraction. Representative trace of EFS-induced muscle force over time with increasing concentrations of dexmedetomidine (b) and expressed as percent
change from the initial baseline EFS-induced contraction (c). Control tracheal rings treated with the vehicle DMSO (0.1%) serves as a time control. Mean± SEM
(n=4). *p<0.05
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To further distinguish between neural and direct air-
way smooth muscle mechanisms in attenuating dexme-
detomidine’s effect on airway smooth muscle
contraction, we contracted the airway smooth muscle
with exogenous acetylcholine added to the buffer (inde-
pendent of neural release) and attempted to directly
relax an established contraction with dexmedetomidine.
Dexmedetomidine (100 μM) attenuated contractile
muscle force induced by the exogenous addition of the
contractile agonist acetylcholine while remifentanil did
not (Fig. 3). The mean difference between control and
dexmedetomidine at 100 μM was 53.4% (103 ± 3.65 vs
49.6 ± 10.5%; p = 0.0061). The exogenouse acetylcholine-
induced contractile muscle force was 52.3% after
1000 μM lidocaine, but after statistical adjustment for
multiple concentration points, this failed to reach statis-
tical significance (103 ± 3.69 vs 50.7 ± 13.6%; p = 0.03).
In addition to parasympathetic cholinergic fibers traveling
in the vagus nerve, another class of nerves (C-fibers) known
as non-adrenergic non-cholinergic (NANC) nerves also
participate in afferent and efferent irritant reflexes in the
upper airway and trachea. A synthetic analogue of capsaicin,
N-vanillylnonanamide, a prototypical C-fiber stimulus in the
somatosensory system in mammalian lungs, was used to
induce TRPV1 receptor-mediated C-fiber activation [25]. In
these tracheal rings the activation of C-fibers releases
substance P which acts on neurokinin receptors on the air-
way smooth muscle to induce contraction. As expected, lido-
caine and another local anesthetic, bupivacaine, decreased
capsaicin-induced contractions, and this effect was mediated
by tetrodotoxin insensitive sodium channels since tetrodo-
toxin at 1 μM had no effect. Dexmedetomidine at 100 μM
also significantly decreased this contraction (expressed as a
decrease in the ratio of the capsacin/acetylcholine-induced
contractions) (mean difference 0.305 (control capsaicin/
acetylcholine contraction− 100 μM dexmedetomidine capsa-
icin/acetylcholine contraction); 0.636 ± 0.0698 vs 0.331 ±
0.0829; p= 0.01) while remifentanil had no effect (Fig. 4). The
mean differences in the capsaicin/acetylcholine contraction
ratios between control and lidocaine at 100 μM were 0.165
(0.673 ± 0.0399 vs 0.508 ± 0.0346; p= 0.02), 0.215 at 200 μM
(0.673 ± 0.0399 vs 0.458 ± 0.0676; p= 0.03) and 0.357 at
1000 μM (0.673 ± 0.0399 vs 0.316 ± 0.0365; p= 0.002). The
mean difference in the capsaicin/acetylcholine contraction ra-
tio between control and bupivacaine at 200 μM was 0.473
(0.673 ± 0.0399 vs 0.200 ± 0.112; p= 0.001).
In the current experiments, dexmedetomidine (0.1–
100 μM) was added to an external buffer bathing a seg-
ment of airway tissue. The actual achieved tissue con-
centrations of dexmedetomidine at the site of action
(nerve or smooth muscle) is dependent on many factors
that determine passive tissue penetration. We sought to
determine what the actual average tissue concentration
of dexmedetomidine was at 30 min after buffer addition
in order to more practically relate the average tissue
concentrations to plasma concentrations achieved dur-
ing clinical use. The measured tissue dexmedetomidine
concentrations are shown in Table 1. For buffer concen-
trations of 1, 10 and 100 μM dexemedetomidine, the
average tissue concentration ranged from 0.54 to 26 nM
which is within the clinically achieved plasma concentra-
tions (~5 nM) achieved with dexmedetomide infusions.
Discussion
In the operating room, clinicians frequently encounter a
patient where intubation of the trachea needs to occur while
Fig. 2 Effect of dexmedetomidine (a), remifentanil (b), lidocaine (c) and tetrodotoxin (d) on acetylcholine (Ach) release from guinea pig tracheal
rings in response to cholinergic EFS. Data were normalized to an initial measurement of Ach release obtained before addition of drugs.
Mean ± SEM (n = 7). *p < 0.05, **p < 0.01 significant difference from control
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maintaining spontaneous ventilation and while avoiding
agitation, stress, cough and bronchoconstriction. The same
type of patient may also require a smooth extubation in the
operating room or a controlled ventilator weaning process
in the intensive care unit. Failure to successfully wean from
mechanical ventilation can lead to days of additional re-
quirement for mechanical ventilatory support with its asso-
ciated morbidities such as ventilator associated pneumonia.
Various medications have been utilized to achieve a smooth
awake intubation or extubation which have been particularly
focused on the avoidance of cough and bronchoconstriction,
which may lead to serious complications such as hypoxemia
and airway trauma. Cough and bronchoconstriction are nat-
ural airway protective reflexes that are mediated by the same
type of irritant receptors resulting in the activation of separ-
ate afferent and efferent neural pathways [26]. In the current
study we questioned whether clinically used anesthetic
agents modulate upper airway responses by modulating
cholinergic or C-fiber neural activity and/or have a direct re-
laxant effect on airway smooth muscle. Although these
Fig. 4 Reduction of capsaicin-induced contraction in guinea pig tracheal rings. Tracheal rings were pretreated with 1–100 μM dexmedetomidine,
0.1–10 μM remifentanil, 10–1000 μM lidocaine, 200 μM bupivacaine or 1 μM tetrodotoxin for 20 min before contraction with 10 μM capsaicin.
Dexmedetomidine at 100 μM significantly reduced this contraction (a) but remifentanil had no effect (b). Local anesthetics lidocaine and bupivacaine
(Bupi) attenuated this C-fiber mediated contraction, which are mediated by tetrodotoxin (TTX) –resistant sodium channels. Mean ± SEM (n= 6).
*p< 0.05, **p< 0.01
Fig. 3 Relaxant effect of dexmedetomidine and lidocaine on exogenous acetylcholine (Ach)-induced contraction of guinea pig tracheal rings.
a Representative trace of Ach-induced contraction and subsequent relaxation or sustained contraction. b, c, d Following stable Ach-induced
contractions, 0.1–100 μM of dexmedetomidine, 2 nM–10 μM of remifentanil, 10–1000 μM of lidocaine or vehicle control (DMSO or water) was
added to the buffer solutions and muscle force change was measured. Mean ± SEM (n = 5). **p < 0.01
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agents may also contribute to airway tone, or alter the
hypercapnic ventilatory response [14] and hypoxic control
of breathing [27] in vivo through central effects at the level
of the brain or spinal cord, we utilized an ex vivo model in
order to assess the peripheral airway effects of these agents.
The primary findings were that dexmedetomidine was
most potent at inhibiting cholinergic nerve activation, a
peripheral parasympathetic neural pathway well appreci-
ated to mediate reflex-induced bronchoconstriction via
the release of acetylcholine.
A large number of clinical studies support the utility of
the α2 adrenoceptor agonist dexmedetomidine in patients
who require smooth intubation or extubation of the tra-
chea [28–30] or who require sedation during prolonged
ventilator support. In mechanically ventilated patients,
dexmedetomidine was reported to improve respiratory
mechanics by increasing compliance [31]. Previous in vivo
animal studies showed that dexmedetomidine prevented
histamine mediated bronchoconstriction in dogs using
high-resolution computed tomographic imaging [32] and
acetylcholine-induced increases in total lung resistance
was blocked by dexmedetomidine in guinea pigs [33]. In
vitro, dexmedetomidine was shown to block carbachol-
induced smooth muscle tension in guinea pig tracheal ring
preparations [33] and methacholine-induced contraction
in rats [34], suggesting that dexmedetomidine may have a
direct inhibitory effect on airway smooth muscle contrac-
tion in the absence of neural stimulation. Although the ef-
fect of α2 adrenoceptor agonists on EFS-induced airway
smooth muscle contraction has been studied [22, 35],
these previous studies only measured a change in smooth
muscle contractile force which does not distinguish
between a pre-junctional neural effect versus a post-
junctional airway smooth muscle effect. In contrast, in the
current study we have directly measured acetylcholine
release as well as smooth muscle contractile force under
both neural stimulation of acetylcholine release or the
exogenous addition of acetylcholine, in the presence of
several clinically used anesthetic agents commonly chosen
during awake instrumentation of the upper airway. We
found that the α2 adrenoceptor agonist dexmedetomidine
(10 μM) was most potent at reducing cholinergic EFS-
induced acetylcholine release (see Fig. 5 for summary) and
resultant smooth muscle contraction in guinea pig trachea
consistent with the presence of α2 adrenoceptors on the
prejunctional side of the postganglionic parasympathetic
nerve [22].
At higher concentrations (100 μM) dexmedetomidine
directly relaxed airway smooth muscle that had been
contracted with acetylcholine (see Fig. 5 for summary),
suggesting that dexmedetomidine’s clinical effect on at-
tenuating airway responses may not be limited to its ef-
fect on presynaptic neurotransmission. In other words,
dexmedetomidine not only provides inhibition of reflex
bronchoconstriction, but also has potential as an effect-
ive bronchodilator in patients with active bronchocon-
striction. Our findings are consistent with previous
studies demonstrating dexmedetomidine’s direct inhibi-
tory effects on carbachol-induced guinea pig airway
smooth muscle contraction [33], and inhibition of
methacholine-induced contraction in rats [34]. α2 adre-
noceptor mediated calcium signaling has been studied in
the cardiovascular system using isolated rat aorta [36]
and is responsible for dexmedetomidine-induced vascu-
lar smooth muscle contraction via peripheral α-2B adre-
noceptor activation, however, the potential effect of
dexmedetomidine on calcium signaling in airway smooth
muscle remains to be elucidated.
Dexmedetomidine (100 μM) also reduced capsaicin-
induced airway smooth muscle contraction, suggesting
an effect on efferent C-fiber mediated release of tachyki-
nins (see Fig. 5 for summary). Further studies measuring
substance P and/or neurokinin A release would confirm
the mechanism for this finding. Guler et. al., reported
that a single-dose bolus injection of dexmedetomidine
before tracheal extubation attenuates airway reflexes
measured by a coughing score [29]. Our finding that
dexmedetomidine attenuates efferent C-fiber mediated
contraction would provide a possible mechanistic
basis for this clinical observation.
The clinically recommended intravenous infusions of
dexmedetomidine are in the range of 0.2 – 0.7 μg/kg/h to
achieve plasma concentrations of 0.3–2.5 ng/ml [37]. 2.5 ng/
ml corresponds to approximately 12 nM. Although the ef-
fective concentrations in the external buffer in organ bath
studies were higher than those reported in plasma during
clinical use, it is difficult to make direct comparisons be-
tween exogenous buffer concentrations in an organ bath and
plasma concentrations in vivo. Therefore, we measured tra-
cheal tissue dexmedetomidine concentrations after tracheal
rings were incubated in the buffer containing various buffer
concentrations of dexmedetomidine, and found that the tis-
sue concentrations (0.54–26 nM) were within the range of
plasma concentrations achieved in clinical use.
At least four types of innervation are present in the air-
ways including cholinergic nerves that release acetylcholine,
adrenergic sympathetic nerves that release norepinephrine
and excitatory or inhibitory nonadrenergic noncholinergic
nerves (C-fibers) which release substance P, vasoactive in-
testinal polypeptide (VIP), calcitonin gene-related peptide
(CGRP) and nitric oxide. In guinea pig trachea, an
Table 1 Dexmedetomidine concentration
Added in organ bath buffer (μM) 1 10 100
Tracheal ring tissue, Mean ± SEM (nM) 0.54 ± 0.082 3.6 ± 0.39 26 ± 3.9
Table 1 tissue concentrations of dexmedetomidine in guinea pig tracheal rings
(n = 5 animals). Guinea pig tracheal rings were incubated for 30 mins in buffer
with 1–100 μM dexmedetomidine. Following extraction, average penetrating
tissue concentrations of dexmedetomidine were deteremined by HPLC – MS/MS
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ultrastructural study revealed close proximity of adrenergic
and cholinergic nerve varicosities [38] suggesting presynap-
tic modulation of acetylcholine release by the adrenergic
system. Indeed, presynaptic adrenergic inhibition of cholin-
ergic neurotransmission in cardiac vagal nerve terminals
[39] was reported. Therefore, we questioned whether ef-
fects of dexmedetomidine on cholinergic EFS-induced con-
tractions could be mediated by dexmedetomidine acting
upon sympathetic nerves which in turn modulated para-
sympathetic cholinergic nerves or directly on β2 adreno-
ceptors on airway smooth muscle to induce relaxation.
Virtanen et al. reported in receptor binding experiments
and isolated organs that medetomidine was devoid of affin-
ity or effects on β1 or β2 adrenoceptors [9], but the highest
concentration of medetomidine evaluated in those ex-
periments was 10 μM. To exclude the possibility that in
the current study, 100 μM of dexmedetomidine was
activating β2 adrenoceptors on cholinergic nerves or
airway smooth muscle, 1 μM propranolol (non-selective
β-adrenoceptor antagonist) was included in the organ
bath buffer. Even in the presence of propranolol, cholin-
ergic EFS-induced contraction was reduced by dexme-
detomidine (data not shown).
Remifentanil is another agent frequently used during
awake intubation or extubation of the trachea that has
analgesic and antitussive properties. Previous clinical
studies comparing dexmedetomidine and remifentanil
demonstrated relatively similar awake intubation and
post-intubation conditions, with similar efficacies for
sedation levels, hemodynamic profiles and the success
rates of intubation [28, 40]. The advantages of remifenta-
nil include its ultra-short duration of action with a con-
sistent half-life, suppression of coughing and attenuation
of cardiovascular responses during airway manipulation,
but with some disadvantages including oxygen desatur-
ation and a higher incidence of awareness during intub-
ation. Previously, EFS-induced cholinergic responses
were reported to be inhibited by a μ-opioid receptor
agonist in guinea pig [41] and human [6] airways in
EFS-stimulus frequency-dependent manner, but in these
previous studies direct measurements of exogenous
acetylcholine-induced contractions or neural acetylcho-
line release were not performed. In the present study,
remifentanil did not inhibit 30Hz EFS-induced contrac-
tion which is consistent with previous reports using a se-
lective μ-opioid receptor agonist [6, 42]. In contrast,
Fig. 5 Schematic diagram of dexmedetomidine’s effect on airway smooth muscle (ASM) contractile tone. Sensory information from the upper airway
(e.g. irritation by endotracheal tubes or suction catheters) reaches the brain medulla (nucleus tractus solitarius (NTS)) via afferent sensory pathways.
Signaling in the NTS is mediated by neurotransmitters including γ-aminobutyric acid (GABA), glutamate and neurokinins, and sends projections to the
airway-related vagal preganglionic neurons (AVPN). These neurons are the origin of the parasympathetic nerves, which, after synapsing at peripheral
parasympathetic ganglia, release acetylcholine (Ach) from post-ganglionic cholinergic nerves. Released Ach binds to muscarinic receptors (M3 on ASM)
and causes ASM contraction. The ganglionic M1 muscarinic receptor is known to facilitate neurotransmission, and neuronal presynaptic M2 muscarinic
receptors are known to inhibit Ach release. C-fiber efferents express TRPV1 (transient receptor potential family vanilloid 1) which is a receptor for
capsaicin, which induces the release of substance P which binds to the neurokinin (NK) receptors and also facilitates ASM contraction. In the current
study, we demonstrated that: (1) dexmedetomidine inhibits Ach release from postganglionic cholinergic nerves; (2) dexmedetomidine directly relaxes
an Ach-induced ASM contraction; and (3) dexmedetomidine attenuates C-fiber mediated contraction
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remifentanil did attenuate a 2Hz EFS-induced contrac-
tion, and the attenuation was reversed by the opioid re-
ceptor antagonist naloxone (data not shown). However,
we did not detect a reduction in the amount of acetyl-
choline released at 2Hz by remifentanil indicating that
the attenuation of contractile force at 2Hz is μ-opioid re-
ceptor mediated but not due to decreased acetylcholine
release. It is possible that the inhibition of EFS-induced
contractions by opioid agonists is due to increase in the
release of inhibitory neurotransmitters from nonadrener-
gic noncholinergic nerves, however, testing all possible
neurotransmitters released is beyond the scope of
current study. In the central nervous system, direct
measurement of acetylcholine release in the pontine
brain stem in cats showed decreased release by fentanyl
and morphine, but not by remifentanil [43]. Our study
showed that remifentanil did not attenuate 2Hz EFS-
induced acetylcholine release consistent with this previ-
ous study finding. Additionally, remifentanil had no
effect on direct airway smooth muscle contraction in-
duced by exogenously applied acetylcholine. Taken to-
gether these findings suggest that remifentanil can relax
a 2Hz but not 30Hz EFS-induced contraction mediated
through a μ-opioid receptor but that this relaxation is
not due to a reduction in acetylcholine release. It has
been reported that either intravenous or inhaled lido-
caine can attenuate reflex-induced bronchoconstriction
in humans [44] via direct effects on smooth muscle cells
[45] by decreasing intracellular calcium [46] and via
neural blockade of vagal reflex or cough pathways [47].
Thus, lidocaine is also frequently used as an adjunct to
prevent reflex-induced bronchoconstriction during air-
way manipulation. Lidocaine has also been reported to
relax acetylcholine-induced contraction in rat trachea
[48]. In fact, clinical studies comparing dexmedetomi-
dine and remifentanil [28, 40] also included clinically
relevant doses of lidocaine, such that potential lidocaine
effects can’t be easily distinguished from the effects of
the study drugs. Our results suggests that lidocaine’s ef-
fect on airway are by inhibition of afferent C-fibers and
direct muscle relaxation, and not by inhibition of acetyl-
choline release from cholinergic nerves. Tetrodotoxin,
which is known to abolish cholinergic contractions by
blockade of sodium channels [24], decreased acetylcho-
line release while lidocaine did not. Lidocaine, on the
other hand, attenuated afferent C-fiber mediated con-
traction while tetrodotoxin did not. In the sensory per-
ipheral nervous system, tetrodotoxin-resistant voltage-
gated sodium channels NaV 1.8 and NaV 1.9, which are
found mostly in small dorsal root ganglion cells associ-
ated with thin fibers, play an important role in impulse
generation, and the IC50 for lidocaine blockade of these
impulses was 177 +/− 25 μM [49]. These previous find-
ings are consistent with the present findings which show
an effect of lidocaine on capsaicin-induced contraction
and a lack of effect by tetrodotoxin.
Conclusions
Our findings suggest that dexmedetomidine, but not lido-
caine or remifentanil attenuates acetylcholine release
during cholinergic EFS in the airway and may provide a
plausible mechanism for the observed utility of dexmede-
tomidine in attenuating airway reactivity during airway
manipulation, and in facilitating noninvasive ventilation in
critically ill asthmatics [50] where dysregulated acetylcho-
line release is suggested. Dexmedetomidine also attenuates
C-fiber mediated contraction, which may be an underlying
mechanism for cough suppression by dexmedetomidine.
With its known clinical advantages of establishing a
comfortable, calm patient who is arousable and
cooperative [51] without respiratory depression, dexmede-
tomidine makes an excellent drug of choice during awake
airway instrumentation or during emergence from general
anesthesia when smooth extubation is desired, and for
patients with obstructive airway disease, who are difficult
to wean from mechanical ventilation.
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